Véronique Leblond

TL;DR: HDR with PBSC transplantation obtained a median OS exceeding 5 years in young patients with symptomatic MM, whether performed early, as first-line therapy, or late, as rescue treatment, suggesting early HDT may be preferred because it is associated with a shorter period of chemotherapy.

TL;DR: The outcome of treatment of AL amyloidosis with high-doseMelphalan plus autologous stem-cell rescue was not superior to the outcome with standard-dose melphalanplus dexamethasone.

TL;DR: It is concluded that rituximab is effective and safe in PTLD, with stable responses at 1 year, and the response rate and overall survival might be improved by combining ritUXimab with other treatments.

TL;DR: Bone marrow biopsy with combined phenotyping is sufficient for diagnosis, and splenectomy is therefore unwarranted, and current treatment modalities appear to be ineffective in most patients.

TL;DR: This randomized trial confirmed a benefit ofHDT in terms of EFS and TwiSTT but did not provide evidence for superiority of HDT over CCT in OS of patients aged 55 to 65 years with symptomatic newly diagnosed MM.